Invention Summary
Asthma, an increasingly important global health problem that affects ~ 300 million people worldwide, is characterized by variable airway inflammation and air flow obstruction. Currently available non-invasive methods for diagnosing and monitoring asthma involve measurements of exhaled nitric oxide (NO). Apart from the transient nature of NO, these methods are limited by low sensitivity and an inability to identify the nature and extent of airway inflammation. Measurement of alternative biomarkers in exhaled breath condensate (EBC) that can facilitate molecular phenotyping of asthma, thus enabling targeted treatment and more effective disease management, is an important clinical need.Nitrite in EBC is a promising biomarker for the extent of inflammation and air-flow obstruction in the respiratory tract and is more stable than NO. Rutgers scientists have developed a novel portable device that employs reduced graphene oxide (rGO) as the sensing mechanism for detecting nitrite in very small volumes of EBC. The team has validated the performance of this device on clinical EBC samples. This enzyme-free and label-free method of detecting nitrite in EBC can pave the way for the development of portable breath analyzers for diagnosing and managing changes in respiratory tract inflammation and disease states.Market Applications:Point-of-Care analyzer for detecting and monitoring nitrite, an asthma-associated inflammation biomarker in EBC.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
exhaled nitric oxide
exhaled breath condensate
facilitate molecular phenotyping
enabling targeted treatment
reduced graphene oxide